ADC Therapeutics SA Increase Decrease Through Exercise Of Options
ADC Therapeutics SA (ADCT) reported Increase Decrease Through Exercise Of Options of $0 for the 9-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Notes
ifrs-full:IncreaseDecreaseThroughExerciseOfOptions · last filed 2023-11-07
- ADC Therapeutics SA increase decrease through exercise of options for the quarter ending 2023-09-30 was $0.00.
- ADC Therapeutics SA increase decrease through exercise of options for the quarter ending 2023-06-30 was $0.00.
- ADC Therapeutics SA increase decrease through exercise of options for the quarter ending 2023-03-31 was $0.00.
- ADC Therapeutics SA increase decrease through exercise of options for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
| Period end | Increase Decrease Through Exercise Of Options 3 month | Increase Decrease Through Exercise Of Options 6 month | Increase Decrease Through Exercise Of Options 9 month | Increase Decrease Through Exercise Of Options 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 6-K · filed 2023-11-07 | $0.00 derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $0.00 6-K · filed 2023-08-08 | $0.00 6-K · filed 2023-08-08 | $0.00 derived: sum of 3 quarters · filed 2023-08-08 | $0.00 derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | $0.00 6-K · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2023-05-09 | $0.00 derived: sum of 3 quarters · filed 2023-11-07 | $0.00 derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | $0.00 derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 derived: sum of 3 quarters · filed 2023-11-07 | $0.00 20-F · filed 2023-03-15 |
| 2022-09-30 | $0.00 6-K · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 6-K · filed 2023-11-07 | $262.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $0.00 derived: 6-K 6 month − 6-K 3 month · filed 2023-08-08 | $0.00 6-K · filed 2023-08-08 | $262.00K derived: sum of 3 quarters · filed 2023-08-08 | $543.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $0.00 6-K · filed 2023-05-09 | $262.00K derived: sum of 2 quarters · filed 2023-05-09 | $543.00K derived: sum of 3 quarters · filed 2023-05-09 | $775.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $262.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $543.00K derived: sum of 2 quarters · filed 2023-03-15 | $775.00K derived: sum of 3 quarters · filed 2023-03-15 | $778.00K 20-F · filed 2023-03-15 |
| 2021-09-30 | $281.00K 6-K · filed 2022-11-08 | $513.00K derived: sum of 2 quarters · filed 2022-11-08 | $516.00K 6-K · filed 2022-11-08 | |
| 2021-06-30 | $232.00K 6-K · filed 2022-08-09 | $235.00K 6-K · filed 2021-08-03 | ||
| 2021-03-31 | $3.00K 6-K · filed 2022-05-09 | |||
| 2020-12-31 | $54.00K 20-F · filed 2023-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |